What vepdegestrant is
Most breast cancers are driven by the estrogen receptor (ER). Standard hormone therapies either lower estrogen or block the receptor. Vepdegestrant, developed by Arvinas with Pfizer, works differently. It is a PROTAC (proteolysis-targeting chimera), a two-ended molecule that grabs the estrogen receptor with one end and a cellular "tagging" enzyme with the other. The tagged receptor is then destroyed by the cell's own protein-disposal system.
According to Arvinas, it is the first PROTAC to be approved by the FDA, a milestone for the wider field of targeted protein degradation.
Why the ESR1 mutation matters
After months of hormone therapy, many breast cancers develop mutations in ESR1, the gene for the estrogen receptor. These mutations can keep the receptor switched on even without estrogen, making older treatments less effective. A drug that destroys the receptor outright is designed to overcome this. That is also why a blood test for ESR1 mutations, a companion diagnostic, decides who is eligible. See What Is Precision Medicine?
Clinical evidence: VERITAC-2
VERITAC-2 randomized 624 patients whose ER-positive, HER2-negative advanced breast cancer had progressed after earlier therapy, comparing vepdegestrant with fulvestrant, an injected hormone therapy.
| Population | Vepdegestrant (median PFS) | Fulvestrant (median PFS) | Hazard ratio |
|---|---|---|---|
| ESR1-mutated (270 patients) | 5.0 months | 2.1 months | 0.58 (NEJM); 0.57 (FDA) |
| All patients | 3.8 months | 3.6 months | 0.83 (p = 0.07, not significant) |
Sources: Campone et al., NEJM (2025); FDA approval announcement. The two hazard ratios for the ESR1 group come from analyses reported separately by the investigators and the FDA.
Grade 3 or higher adverse events occurred in 23.4% of patients on vepdegestrant and 17.6% on fulvestrant, and treatment was stopped because of adverse events in 2.9% and 0.7%, respectively.
Regulatory status
The FDA approved Veppanu (vepdegestrant) on May 1, 2026, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The FDA also approved the Guardant360 CDx blood test as its companion diagnostic. The recommended dose is 200 mg once daily with food, and the FDA acted one month ahead of its goal date.
Scientific perspective
VERITAC-2 shows why approvals in oncology increasingly target biomarker-defined populations. In the full trial the benefit was small and not statistically significant. In patients with ESR1 mutations, the group the drug's mechanism is designed for, the benefit was clear. The label follows the evidence: approval covers the ESR1-mutated group only.
Development perspective
- Approved use: ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy. No benchmark is shown for an approved program.
- Commercialization: Arvinas and Pfizer said they planned to select a third party to commercialize Veppanu (company-reported).
- Class significance: success here supports the broader PROTAC and protein-degradation approach, which many companies are applying to other targets.
Development timeline
- Jan 31, 2025VERITAC-2 Phase 3 trial reaches primary completion. Registry
- May 31, 2025VERITAC-2 published: progression-free survival 5.0 vs 2.1 months in ESR1-mutated patients; not significant in the overall population. Peer-reviewed
- May 1, 2026FDA approves Veppanu (vepdegestrant) with the Guardant360 CDx companion diagnostic, one month ahead of its goal date. Regulator
What could change the outlook
- Commercial launch arrangements, including the third-party partner Arvinas and Pfizer said they would select (company-reported).
- Competition from other oral estrogen receptor degraders approved for ESR1-mutated breast cancer.
- Whether the PROTAC approach succeeds against other targets, which would make vepdegestrant the first of a broader class.
- VERITAC-3 and other combination studies listed in the registry.
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Vepdegestrant. Company-reported, not independently verified.
- Quarterly reportCompany-reportedNov 3, 2026
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
External expenses include (i) program-specific expenses, which decreased by $6.7 million, primarily driven by a decrease in the vepdegestrant (ARV-471) program of $14.2 million, partially offset by increases in the ARV-027, ARV-6723, and ARV-393 programs of $4.6 million, $3.3 million, and $3.2 million...
- Quarterly reportCompany-reportedNov 3, 2026
IGNITING A TRANSFORMATIVE CHANGE in the fight for patients with cancer and neurodegenerative diseases
PROTAC:, proteolysis targeting chimera a. vepdegestrant, bavdegalutamide, luxdegalutamide (JSB462), ARV-102, ARV-393, ARV-806, ARV-027, ARV-6723 Our experienced and talented team is advancing a new therapeutic modality for patients 4 History of FIRSTS with our novel Clinical trials in oncology Discovery Clinical...
- RegulatoryCompany-reportedAug 13, 2026
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANU TM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth...